Pacific Biosciences (NASDAQ:PACB) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced a collaboration with DNAstack to launch the world’s first global federated dataset of HiFi whole genome sequencing ...
Pacific Biosciences PACB underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, ...
Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...
Pacific Biosciences (NASDAQ:PACB) is preparing to release its quarterly earnings on Thursday, 2026-02-12. Here's a brief overview of what investors should keep in mind before the announcement.
Ratings for Pacific Biosciences (NASDAQ:PACB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...
For the quarter ended March 2025, Pacific Biosciences of California (PACB) reported revenue of $37.15 million, down 4.3% over the same period last year. EPS came in at -$0.15, compared to -$0.26 in ...
The chart has 2 X axes displaying Time, and Time. The chart has 2 Y axes displaying symbol price, and symbol volume. Created with Highcharts 12.5.0 ...
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results